GHB Immediate Release Tablet Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Sodium oxybate, used to treat narcolepsy and other conditions, poses challenges due to its high water solubility and hygroscopic nature, making it difficult to formulate into effective solid unit dosage forms that ensure immediate release and bioequivalence with existing oral solutions, particularly at high doses required for clinical effectiveness.
Innovation Solution
Development of compressed immediate release tablet formulations with high drug loading, utilizing a combination of GHB sodium salt, lubricants, binders, and surfactants to facilitate rapid dissolution and bioequivalence with Xyrem® oral solution, while minimizing excipient use and tablet size for improved patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If sodium oxybate is formulated as a compressed tablet with common excipients, then it provides a solid unit dosage form, but it exhibits poor dissolution and fails to achieve immediate release
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by using a specific excipient combination (microcrystalline cellulose, croscarmellose sodium, and sodium lauryl sulfate) in optimized proportions. This parameter change enables the tablet to disintegrate rapidly and release sodium oxybate immediately, achieving both solid dosage form stability and rapid dissolution
Solution Approach 2:
The patent creates a composite tablet formulation by combining sodium oxybate with specific excipients (microcrystalline cellulose as filler, croscarmellose sodium as disintegrant, and sodium lauryl sulfate as surfactant) in a proprietary blend. This composite material approach allows the tablet to maintain structural integrity while achieving rapid disintegration and immediate drug release
2Volume of moving object
If the tablet contains high drug loading of sodium oxybate, then the tablet size is reduced for better compliance, but formulation challenges increase due to hygroscopic nature
Solution Approach 1:
The patent optimizes the formulation parameters by incorporating hydrophilic excipients (microcrystalline cellulose and croscarmellose sodium) that modify the moisture absorption characteristics of hygroscopic sodium oxybate. This parameter change allows high drug loading (70-90% w/w) while preventing excessive hygroscopicity and maintaining manufacturability
Solution Approach 2:
The patent uses hydrophilic excipients as intermediary materials between the hygroscopic drug and the environment. These intermediaries (microcrystalline cellulose and croscarmellose sodium) act as moisture barriers and binding agents, enabling high drug loading while controlling the hygroscopic nature of sodium oxybate during manufacturing
3Speed
If the tablet uses minimal excipients, then the drug release is faster, but tablet structural integrity and manufacturability are compromised
Solution Approach 1:
The patent carefully balances excipient quantities to achieve optimal drug release while maintaining tablet integrity. By using croscarmellose sodium (1-5% w/w) as disintegrant and sodium lauryl sulfate (0.5-2% w/w) as surfactant in controlled proportions, the formulation achieves rapid disintegration and drug release without compromising the structural integrity needed for manufacturing
Solution Approach 2:
The patent applies different functional properties to different components locally: microcrystalline cellulose provides structural framework and binding, croscarmellose sodium provides disintegration capability in specific regions, and sodium lauryl sulfate provides surfactant action at the drug-excipient interface. This local quality differentiation enables both rapid drug release and adequate tablet strength
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations achieve rapid drug release within 30 minutes to 1 hour, ensuring bioequivalence with Xyrem®, improving patient compliance and convenience by providing a solid unit dosage form that maintains therapeutic levels effectively.
Implementation Method 1
The immediate release formulations described herein include a surfactant, such as sodium lauryl sulfate
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.